Sionna: building better correctors to compete with Vertex’s CF therapies

Sanofi spinout Sionna believes its CFTR-stabilizing compound could outperform Vertex’s blockbuster therapies in the clinic and capture a share of the multibillion dollar market for cystic fibrosis treatments.

The Waltham, Mass., start-up is aiming to submit an IND within a year for its therapy targeting the first nucleotide-binding domain (NBD1) of CFTR. Stabilization of NBD1 could restore function of ΔF508 in the protein, mutations of which are the most common cause of CF...